GYRE THERAPEUTICS, INC.
GYREUS売上高
$117M
百万USD
営業利益
$11M
百万USD
純利益
$10M
百万USD
ROE
9.3%
最新FY
EPS
$0.02
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q1 | $1M | $-22M | - |
| FY2021 | Q2 | $1M | $-20M | - |
| FY2021 | Q3 | $2M | $-25M | - |
| FY2021 | FY | $7M | $-88M | - |
| FY2022 | Q1 | $1M | $-15M | - |
| FY2022 | Q2 | - | $52M | $1.64 |
| FY2022 | Q3 | - | $-5M | $-0.16 |
| FY2022 | FY | - | $-8M | $-0.26 |
| FY2023 | Q1 | - | $0M | $0.01 |
| FY2023 | Q2 | - | $-2M | $-0.07 |
| FY2023 | Q3 | - | $-2M | $-0.04 |
| FY2023 | FY | $113M | $-85M | $-1.41 |
| FY2024 | Q1 | $27M | $10M | $0.03 |
| FY2024 | Q2 | $25M | $5M | $0.01 |
| FY2024 | Q3 | $25M | $3M | $0.01 |
| FY2024 | FY | $106M | $18M | $0.05 |
| FY2025 | Q1 | $22M | $4M | $0.00 |
| FY2025 | Q2 | $27M | $2M | $0.00 |
| FY2025 | Q3 | $31M | $6M | $0.03 |
| FY2025 | FY | $117M | $10M | $0.02 |
| FY2026 | Q1 | $23M | $-10M | $-0.10 |
財務データ
| 指標 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 売上高 | - | - | $0M | $0M | $21M | $7M | - | $113M | $106M | $117M |
| 営業利益 | $-20M | $-22M | $-34M | $-57M | $-57M | $-88M | $-9M | $-67M | $16M | $11M |
| 純利益 | $-17M | $-22M | $-30M | $-55M | $-56M | $-88M | $-8M | $-85M | $18M | $10M |
| 総資産 | $38M | $40M | $125M | $99M | $95M | $56M | $28M | $117M | $125M | $166M |
| 純資産 | - | - | - | - | - | - | - | $14M | $98M | $142M |
| 自己資本 | $16M | $31M | $120M | $68M | $76M | $41M | $-22M | $-16M | $63M | $106M |
| 営業CF | - | - | $-29M | $-44M | $-55M | $-84M | $-33M | $26M | $-4M | $1M |
| EPS | - | - | - | - | - | - | $-0.26 | $-1.41 | $0.05 | $0.02 |
| BPS | $16.07 | $2.59 | $10.02 | $5.66 | $2.43 | $1.31 | $-0.57 | $-0.19 | $0.68 | $1.09 |
| ROE | -105.4% | -70.1% | -25.1% | -80.7% | -73.9% | -214.0% | 38.0% | 540.1% | 28.3% | 9.3% |